Sagimet Biosciences' Partner Ascletis Receives NMPA Acceptance for Denifanstat NDA in China; Advances MASH Combination Therapy

summarizeSummary

Sagimet Biosciences announced its partner Ascletis received NMPA acceptance for a New Drug Application for denifanstat in moderate to severe acne in China, alongside positive Phase 3 data and plans to advance a denifanstat/resmetirom combination into Phase 2 for MASH cirrhosis.

check_boxKey Events

• NMPA Acceptance for Denifanstat NDA in China

  Sagimet's partner, Ascletis Bioscience, received acceptance from China's National Medical Products Administration (NMPA) for a New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne, following positive topline results from an open-label Phase 3 trial.

• Advancement of MASH Combination Therapy

  The company completed a Phase 1 pharmacokinetic (PK) clinical trial of a denifanstat and resmetirom combination, with plans to initiate a Phase 2 proof-of-concept trial in F4 MASH (cirrhosis) patients in the second half of 2026. Sagimet also secured a global, exclusive license to TAPI's innovative forms of resmetirom API for a fixed-dose combination product.

• Full Year 2025 Financial Results

  Sagimet reported a net loss of $51.0 million for the full year ended December 31, 2025, compared to $45.6 million for the full year 2024. Research and development expenses for the year were $39.1 million, and general and administrative expenses were $17.8 million.

• Cash Runway Extended

  Cash, cash equivalents, and marketable securities totaled $113.1 million as of December 31, 2025. The company expects this cash position to fund current operations through Q3 2027.

auto_awesomeAnalysis

Sagimet Biosciences reported significant progress in its pipeline, most notably the acceptance of a New Drug Application (NDA) by China's National Medical Products Administration (NMPA) for denifanstat, developed by its partner Ascletis, for moderate to severe acne. This regulatory milestone, following positive Phase 3 open-label trial results, marks a crucial step towards potential commercialization in a major market. Additionally, the company completed a Phase 1 pharmacokinetic trial for a denifanstat and resmetirom combination, with plans to initiate a Phase 2 trial in the second half of 2026 for MASH patients with F4 fibrosis, an area with no approved treatments. While the company reported an increased net loss for the full year 2025 and a decrease in cash, cash equivalents, and marketable securities to $113.1 million, it projects its current resources will fund operations through Q3 2027, providing a solid runway for these clinical advancements. The concurrent 10-K filing will provide a more comprehensive annual report.